openPR Logo

Press Releases from Synagis (Pediatric RSV) (1 total)

Synagis (Pediatric RSV) - Forecast And Market Analysis To 2022

Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Synagis (Pediatric RSV) Forecast and Market Analysis to 2022. Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission typically occurs during the winter and early spring months. The virus is spread through the air by an infected persons sneeze or

Go To Page:   1